Biomarkers in DNA Samples From Younger Patients With Newly Diagnosed Acute Myeloid Leukemia Receiving Gemtuzumab Ozogamicin

Children's Oncology Group

Status

Completed

Conditions

Leukemia

Treatments

Other: laboratory biomarker analysis

Genetic: DNA analysis

Genetic: polymerase chain reaction

Other: pharmacological study

Study type

Observational

Funder types

NETWORK

NIH

Identifiers

NCT01139320

AAML10B3

NCI-2011-02220 (Registry Identifier)

CDR0000671448 (Other Identifier)

COG-AAML10B3 (Other Identifier)

Details and patient eligibility

About

RATIONALE: Studying samples of DNA from patients receiving gemtuzumab ozogamicin may help doctors learn more about the effects of gemtuzumab ozogamicin on cells. It may also help doctors understand how well patients respond to treatment.

PURPOSE: This research study is studying biomarkers in DNA samples from younger patients with newly diagnosed with acute myeloid leukemia receiving gemtuzumab ozogamicin.

Full description

OBJECTIVES:

To analyze candidate-coding polymorphisms in CD33 of DNA samples from children with newly diagnosed acute myeloid leukemia treated with gemtuzumab ozogamicin on COG-AAML03P1.
To determine the association between these polymorphisms and clinical response of patients treated with this regimen.

OUTLINE: Archived DNA samples are analyzed for candidate polymorphisms in CD33 by PCR-based sequencing.

Enrollment

300 estimated patients

Sex

All

Ages

Under 21 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS: